1265229-25-1

CH5183284 是一种选择性口服有效的FGFR抑制剂，对FGFR1，FGFR2，FGFR3，和 FGFR4的IC50分别为 9.3 nM，7.6 nM，22 nM，和 290 nM 。Phase 1。

In cell-based assay, CH5183284 prevents autophosphorylation of FGFR1, FGFR2, and FGFR3 at 100 to 300 nM in the DMS114 (FGFR1 amplification), SNU-16 (FGFR2 amplification), and KMS11 [t(4;14) translocation and FGFR3 Y373C mutation] cell lines. CH5183284 thus produces selective antiproliferative activity against cancer cell lines harboring genetic alterations in FGFR. CH5183284 also inhibit FGFR2 harboring one type of the gatekeeper mutation (V564F) that causes resistance to other FGFR inhibitors.

CH5183284 (100 mg/kg/day, p.o.) shows selective and significant antitumor activity against xenografts with FGFR genetic alterations such as KG1 (leukemia, FGFR1OP-FGFR1 fusion), SNU-16 (gastric cancer, FGFR2 amplification), MFE-280 (endometrial cancer, FGFR2 S252W mutation), UM-UC-14 (bladder cancer, FGFR3 S249C mutation), and RT112/84 (bladder cancer, FGFR3-TACC3 fusion).

CH5183284 (Debio-1347, FF284)是一种选择性口服有效的FGFR抑制剂，对FGFR1，FGFR2，FGFR3，和 FGFR4的IC50分别为 9.3 nM，7.6 nM，22 nM，和 290 nM 。Phase 1。

Target	Value
FGFR2 (Cell-free assay)	7.6 nM
FGFR1 (Cell-free assay)	9.3 nM
FGFR3 (Cell-free assay)	22 nM
FGFR4 (Cell-free assay)	290 nM

在细胞水平试验中，100 到300 nM 的CH5183284防止DMS114 (FGFR1 扩增)，SNU-16 (FGFR2扩增)，和KMS11 [t(4;14) 易位和FGFR3 Y373C 突变]细胞系中FGFR1，FGFR2，和FGFR3自身磷酸化。CH5183284因此产生对包含FGFR遗传学改变的癌细胞系的选择性抗增殖活性。 FGFR2含有一种门控突变(V564F)，使其抗其他FGFR抑制剂，而CH5183284能够对其产生抑制作用。

CH5183284 (100 mg/kg/day, p.o.)对FGFR遗传学改变的异种移植物，比如KG1 (白血病， FGFR1OP-FGFR1 融合体)，SNU-16 (胃癌，FGFR2 扩增)，MFE-280 (子宫内膜癌，FGFR2 S252W突变体)，UM-UC-14 (膀胱癌，FGFR3 S249C 突变体)，和RT112/84 (膀胱癌，FGFR3-TACC3融合体)产生显著的选择性抗肿瘤活性。